E-LIB Suche - Ergebnisse für: Menon, Rajeev M.

1

Clinical pharmacokinetics and pharmacodynamics of venetocla..:

Salem, Ahmed Hamed ; Menon, Rajeev M.
Clinical and Translational Science. 17 (2024) 5 - p. , 2024

Link: https://doi.org/10.1111/..

2

Pharmacokinetics and immunogenicity of eftozanermin alfa in..:

Biesdorf, Carla ; Guan, Xiaowen ; Siddani, Satya R....
Cancer Chemotherapy and Pharmacology. , 2023

Link: https://doi.org/10.1007/..

3

Venetoclax pharmacokinetics in participants with end‐stage ..:

Noorani, Behnam ; Menon, Rajeev M. ; Chen, Xin...
British Journal of Clinical Pharmacology. 90 (2023) 3 - p. 748-758 , 2023

Link: https://doi.org/10.1111/..

4

Venetoclax in biomarker‐selected multiple myeloma patients:..:

Badawi, Mohamed ; Coppola, Sheryl ; Eckert, Doerthe...
Hematological Oncology. 42 (2023) 1 - p. , 2023

Link: https://doi.org/10.1002/..

5

Effects of a ritonavir‐containing regimen on the pharmacoki..:

Zha, Jiuhong ; Jiang, Qi ; Yao, Betty B....
Pharmacology Research & Perspectives. 10 (2022) 6 - p. , 2022

Link: https://doi.org/10.1002/..

6

Impact of Multiple Concomitant CYP3A Inhibitors on Venetocl..:

Mukherjee, Dwaipayan ; Brackman, Deanna J. ; Suleiman, Ahmed A....
The Journal of Clinical Pharmacology. 63 (2022) 1 - p. 119-125 , 2022

Link: https://doi.org/10.1002/..

7

Dose adjustment of venetoclax when co-administered with pos..:

Bhatnagar, Sumit ; Mukherjee, Dwaipayan ; Salem, Ahmed Hamed...
Cancer Chemotherapy and Pharmacology. 87 (2021) 4 - p. 465-474 , 2021

Link: https://doi.org/10.1007/..

8

Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subje..:

Salem, Ahmed Hamed ; Dave, Nimita ; Marbury, Thomas...
Clinical Pharmacokinetics. 58 (2019) 8 - p. 1091-1100 , 2019

Link: https://doi.org/10.1007/..

9

An Integrated Population Pharmacokinetic Model Versus Indiv..:

Mittapalli, Rajendar K. ; Stodtmann, Sven ; Friedel, Anna...
The Journal of Clinical Pharmacology. 59 (2019) 9 - p. 1225-1235 , 2019

Link: https://doi.org/10.1002/..

10

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Da..:

Gopalakrishnan, Sathej ; Mensing, Sven ; Menon, Rajeev M..
Clinical Pharmacokinetics. 57 (2018) 11 - p. 1407-1419 , 2018

Link: https://doi.org/10.1007/..

11

Use of depth of response to predict progression‐free surviv..:

Mangal, Naveen ; Salem, Ahmed Hamed ; Menon, Rajeev M..
Hematological Oncology. 36 (2018) 3 - p. 547-553 , 2018

Link: https://doi.org/10.1002/..

12

Effects of chronic kidney disease stage 4, end-stage renal ..:

Shuster, Diana L. ; Menon, Rajeev M. ; Ding, Bifeng...
European Journal of Clinical Pharmacology. 75 (2018) 2 - p. 207-216 , 2018

Link: https://doi.org/10.1007/..

13

Accelerating Drug Development in Pediatric Oncology With th..:

Shebley, Mohamad ; Menon, Rajeev M. ; Gibbs, John P....
The Journal of Clinical Pharmacology. 59 (2018) 5 - p. 625-637 , 2018

Link: https://doi.org/10.1002/..

14

Guiding dose adjustment of amlodipine after co-administrati..:

Mukherjee, Dwaipayan ; Zha, Jiuhong ; Menon, Rajeev M..
Journal of Pharmacokinetics and Pharmacodynamics. 45 (2018) 3 - p. 443-456 , 2018

Link: https://doi.org/10.1007/..

15

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, an..:

Zha, Jiuhong ; Ding, Bifeng ; Wang, Haoyu...
European Journal of Drug Metabolism and Pharmacokinetics. 44 (2018) 1 - p. 43-52 , 2018

Link: https://doi.org/10.1007/..